Merrill keeps Celgene at buy

Celgene Corp. was kept at a buy rating by Merrill Lynch analyst Tom McGahren on news the company updated preliminary data from a small open-label single-arm phase 2 monotherapy study (NHL-002) of Revlimid in the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma (NHL). The updated data are encouraging and consistent with prior data from the trial presented in June in which 31% of evaluable patients had experienced an objective response. Shares of the Summit, N.J.-based pharmaceutical company were down 72 cents, or 1.86%, at $42.58. (CELG)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.